stockrowPTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow PTCT
Alert me
PTC Therapeutics, Inc. (PTCT) Revenue
PTC Therapeutics, Inc.'s revenue for fiscal 2025 was $1.7B, up 114.5% from $806.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.2B. Over the past ten years it has ranged from $36.8M (fiscal 2015) to $1.7B (fiscal 2025) — the current reading is the highest in ten years. PTC Therapeutics, Inc. ranks 23rd of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $1.7B | 114.51% |
| FY2024 | $806.8M | (13.97%) |
| FY2023 | $937.8M | 34.20% |
| FY2022 | $698.8M | 29.75% |
| FY2021 | $538.6M | 41.45% |
| FY2020 | $380.8M | 24.04% |
| FY2019 | $307.0M | 15.96% |
| FY2018 | $264.7M | 36.19% |
| FY2017 | $194.4M | 135.04% |
| FY2016 | $82.7M | 124.95% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $357.8M | (0.75%) |
| Jun 2026 | $360.5M | 32.28% |
| Mar 2026 | $272.6M | 65.51% |
| Dec 2025 | $164.7M | (21.96%) |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| PTCT PTC Therapeutics, Inc. | $1.2B |
| MIRM Mirum Pharmaceuticals, Inc. compare | $670.8M |
| SRRK Scholar Rock Holding Corporation compare | $47.3M |
| COGT Cogent Biosciences, Inc. compare | $23.2M |
| CGON CG Oncology, Inc. compare | $6.2M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| MANE Veradermics Incorporated compare | — |
| IMVT Immunovant, Inc. compare | — |
| KOD Kodiak Sciences Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on PTCT
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement